687 related articles for article (PubMed ID: 17579631)
1. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
Berthiaume M; Laplante M; Tchernof A; Deshaies Y
Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
[TBL] [Abstract][Full Text] [Related]
2. Actions of PPARgamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids.
Berthiaume M; Sell H; Lalonde J; Gélinas Y; Tchernof A; Richard D; Deshaies Y
Am J Physiol Regul Integr Comp Physiol; 2004 Nov; 287(5):R1116-23. PubMed ID: 15256367
[TBL] [Abstract][Full Text] [Related]
3. Early induction of a brown-like phenotype by rosiglitazone in the epicardial adipose tissue of fatty Zucker rats.
Distel E; Penot G; Cadoudal T; Balguy I; Durant S; Benelli C
Biochimie; 2012 Aug; 94(8):1660-7. PubMed ID: 22575275
[TBL] [Abstract][Full Text] [Related]
4. Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats.
Berthiaume M; Laplante M; Festuccia WT; Berger JP; Thieringer R; Deshaies Y
Int J Obes (Lond); 2009 May; 33(5):601-4. PubMed ID: 19223847
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor γ activation favours selective subcutaneous lipid deposition by coordinately regulating lipoprotein lipase modulators, fatty acid transporters and lipogenic enzymes.
Blanchard PG; Turcotte V; Côté M; Gélinas Y; Nilsson S; Olivecrona G; Deshaies Y; Festuccia WT
Acta Physiol (Oxf); 2016 Jul; 217(3):227-39. PubMed ID: 26918671
[TBL] [Abstract][Full Text] [Related]
6. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
7. Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice.
Lee MS; Kim CT; Kim Y
Ann Nutr Metab; 2009; 54(2):151-7. PubMed ID: 19390166
[TBL] [Abstract][Full Text] [Related]
8. Regional differences in the expression of genes involved in lipid metabolism in adipose tissue in response to short- and medium-term fasting and refeeding.
Palou M; Sánchez J; Priego T; Rodríguez AM; Picó C; Palou A
J Nutr Biochem; 2010 Jan; 21(1):23-33. PubMed ID: 19157823
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.
Walker GE; Marzullo P; Verti B; Guzzaloni G; Maestrini S; Zurleni F; Liuzzi A; Di Blasio AM
Obesity (Silver Spring); 2008 Sep; 16(9):1983-91. PubMed ID: 19186324
[TBL] [Abstract][Full Text] [Related]
10. Involvement of adipose tissues in the early hypolipidemic action of PPARgamma agonism in the rat.
Laplante M; Festuccia WT; Soucy G; Gélinas Y; Lalonde J; Deshaies Y
Am J Physiol Regul Integr Comp Physiol; 2007 Apr; 292(4):R1408-17. PubMed ID: 17170230
[TBL] [Abstract][Full Text] [Related]
11. The PPARgamma ligand rosiglitazone influences triacylglycerol metabolism in non-obese males, without increasing the transcriptional activity of PPARgamma in the subcutaneous adipose tissue.
Joosen AM; Bakker AH; Kersten S; Westerterp KR
Br J Nutr; 2008 Mar; 99(3):487-93. PubMed ID: 18177513
[TBL] [Abstract][Full Text] [Related]
12. Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression.
Moore GB; Pickavance LC; Briscoe CP; Clapham JC; Buckingham RE; Wilding JP
Diabetes Obes Metab; 2008 Mar; 10(3):251-63. PubMed ID: 18269641
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism.
Laplante M; Festuccia WT; Soucy G; Gélinas Y; Lalonde J; Berger JP; Deshaies Y
Diabetes; 2006 Oct; 55(10):2771-8. PubMed ID: 17003342
[TBL] [Abstract][Full Text] [Related]
14. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
[TBL] [Abstract][Full Text] [Related]
15. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
Lessard SJ; Rivas DA; Chen ZP; Bonen A; Febbraio MA; Reeder DW; Kemp BE; Yaspelkis BB; Hawley JA
Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
[TBL] [Abstract][Full Text] [Related]
16. Increased de novo lipogenesis in liver contributes to the augmented fat deposition in dexamethasone exposed broiler chickens (Gallus gallus domesticus).
Cai Y; Song Z; Zhang X; Wang X; Jiao H; Lin H
Comp Biochem Physiol C Toxicol Pharmacol; 2009 Aug; 150(2):164-9. PubMed ID: 19393339
[TBL] [Abstract][Full Text] [Related]
17. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
Törüner F; Akbay E; Cakir N; Sancak B; Elbeg S; Taneri F; Aktürk M; Karakoç A; Ayvaz G; Arslan M
Horm Metab Res; 2004 Apr; 36(4):226-30. PubMed ID: 15114521
[TBL] [Abstract][Full Text] [Related]
18. PPARgamma agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control.
Festuccia WT; Laplante M; Berthiaume M; Gélinas Y; Deshaies Y
Diabetologia; 2006 Oct; 49(10):2427-36. PubMed ID: 16906479
[TBL] [Abstract][Full Text] [Related]
19. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
Ljungberg A; Lindén D; Améen C; Bergström G; Oscarsson J
Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
[TBL] [Abstract][Full Text] [Related]
20. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
Chakrabarti R; Misra P; Vikramadithyan RK; Premkumar M; Hiriyan J; Datla SR; Damarla RK; Suresh J; Rajagopalan R
Eur J Pharmacol; 2004 May; 491(2-3):195-206. PubMed ID: 15140637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
